RxDoctor Payments Data

Zareena Shama, MD

Family Medicine · Burleson, TXNPI 1568685501

Payments from drug & device makers

$4,747in general payments, 2019–2025

Across 273 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$676
  • Lilly USA, LLC$583
  • AstraZeneca$578
  • Novo Nordisk$466
  • Pfizer$236
  • Boehringer Ingelheim$195
  • plus $2K from 43 others

What the payments were for

  • Food & beverage$4,747100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,747 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$121,485
Medicare patients
251
Services billed
1,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide200$221,117
JardianceEmpagliflozin116$132,432
EliquisApixaban58$68,571
TrulicityDulaglutide53$60,255
FarxigaDapagliflozin Propanediol42$46,977
XareltoRivaroxaban39$45,838
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$37,844
MounjaroTirzepatide34$34,026
RybelsusSemaglutide19$28,105
DescovyEmtricitabine/Tenofov Alafenam12$25,394
Tresiba Flextouch U-200Insulin Degludec22$19,788
Tresiba Flextouch U-100Insulin Degludec48$19,123
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$7,661
LivaloPitavastatin Calcium14$7,164
SymbicortBudesonide/Formoterol Fumarate25$6,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$466$249,222219 claims
Boehringer IngelheimJardiance$195$132,432116 claims
Lilly USA, LLCTrulicity, Mounjaro$583$94,28187 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$578$91,273116 claims
PfizerEliquis$236$68,57158 claims
Johnson & JohnsonXarelto$99$45,83839 claims
GileadDescovy$12$25,39412 claims
Kowa Pharmaceuticals America, Inc.Livalo$94$7,16414 claims
GSKBreo Ellipta$127$4,00212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →